Posted Fri 20 Nov 2020 1.28pm by Adam
Hi, I'm a HCP working in an ED department. My Consultant Dermatologist has suggested Risankizumab to treat my psoriasis.
With covid and other conditions im a bit nervous, there limited research out there but I'm reading that this IL23 inhibitor although inhibits part of the immunity, it doesn't completely.
Ultimately, would.it be wise to start this treatment, particularly during a pandemic 🤔🤷♂️
Posted Fri 20 Nov 2020 5.22pm by Steview
A P sufferer for over 30 years, through good and bad times.
Welcome Adam, the decision at the end of the day is between your consultant and yourself.
I have not heard of risanizumab but it looks like it is marketed as Skyrizi.
This is another medication in the biologics range of treatments which are immunosuppressants so you are at greater risk of infection.
Saying that there many patients worldwide currently using Biologics for a range of conditions. If the specialists thought patients were at greater risk during Covid, they would probably inform them and ask them to shield or come maybe come off the medication. I can't speak of research on Skyrizi.
In my case I started Biologics in Nov 19 as it was the next treatment available and I wanted to to maintain a good quality of life, which it has done so far. I have not been asked to shield or stop treatment although I am aware I may be at greater risk.
I am in the UK, looks like you are possibly in the US where they may offer different advice.